Randomised clinical trial: A liquid multi-strain probiotic vs. Placebo in the irritable bowel syndrome - A 12 week double-blind study

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 1, 2014, Pages 51-62

  Sisson, G ^a   Ayis, S ^b   Sherwood, R A ^b   Bjarnason, I ^b  

^a DARENT VALLEY HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ACNE; ADULT; ARTICLE; BACTERIAL STRAIN; BLOATING; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; FOLLOW UP; HEADACHE; HEARTBURN; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; VAGINA CANDIDIASIS; VOMITING;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROBIOTICS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84902082646     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12787     Document Type: Article

References (44)

1. NICE. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. Clinical guidelines, CG61. Available at: http://www.nice.org.uk/CG061. Accessed February 2008.
2. Quigley EM, Abdel-Hamid H, Barbara G, et al,. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012; 46: 356-66.
3. Whorwell PJ, McCallum M, Creed FH, Roberts CT,. Non-colonic features of irritable bowel syndrome. Gut 1986; 27: 37-40.
4. Akehurst RL, Brazier JE, Mathers N, et al,. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20: 45562.
5. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW,. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-41.
6. Leong SA, Barghout V, Birnbaum HG, et al,. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163: 929-35.
7. Spiegel B, Harris L, Lucak S, et al,. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol 2009; 104: 1984-91.
8. Spiller R, Aziz Q, Creed F, et al,. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
9. Grundmann O, Yoon SL,. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 2010; 25: 691-9.
10. Chow J, Lee SM, Shen Y, Khosravi A, Mazmanian SK,. Host-bacterial symbiosis in health and disease. Adv Immunol 2010; 107: 243-74.
11. Ghoshal UC, Park H, Gwee KA,. Bugs and irritable bowel syndrome: the good, the bad and the ugly. J Gastroenterol Hepatol 2010; 25: 244-51.
12. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR,. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010; 55: 392-7.
13. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al,. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33.
14. Maukonen J, Satokari R, Matto J, Soderlund H, Mattila-Sandholm T, Saarela M,. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006; 55: 625-33.
15. Pimentel M, Lembo A, Chey WD, et al,. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
16. Gibson PR, Shepherd SJ,. Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol 2010; 25: 252-8.
17. Finamore A, Roselli M, Britti MS, Merendino N, Mengheri E,. Lactobacillus rhamnosus GG and Bifidobacterium animalis MB5 induce intestinal but not systemic antigen-specific hyporesponsiveness in ovalbumin-immunized rats. J Nutr 2012; 142: 375-81.
18. Rousseaux C, Thuru X, Gelot A, et al,. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-7.
19. Verdu EF, Bercik P, Bergonzelli GE, et al,. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127: 826-37.
20. Verdu EF, Bercik P, Verma-Gandhu M, et al,. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55: 182-90.
21. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P,. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9: 15.
22. McFarland LV, Dublin S,. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-61.
23. Farnworth ER,. The evidence to support health claims for probiotics. J Nutr 2008; 138: 1250S-5S.
24. Francis CY, Morris J, Whorwell PJ,. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402.
25. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL,. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11.
26. Spiegel B, Bolus R, Harris LA, et al,. Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther 2009; 30: 1159-70.
27. Sharpstone D, Neild P, Crane R, et al,. Gastric emptying, and small bowel transit, absorption and permeability in AIDS patients with and without diarrhoea. Gut 1999; 45: 70-6.
28. Takeuchi K, Smale S, Premchand P, et al,. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196-202.
29. StataCorp. Statistical Software: Release 12. College Station, TX: StataCorp LP, 2012.
30. IBM Corp. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp, 2010.
31. White IR, Horton NJ, Carpenter J, Pocock SJ,. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011; 342: d40.
32. Bjarnason I, MacPherson A, Hollander D,. Intestinal permeability: an overview. Gastroenterology 1995; 108: 1566-81.
33. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I,. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-60.
34. Dunlop SP, Hebden J, Campbell E, et al,. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-94.
35. O'Mahony L, McCarthy J, Kelly P, et al,. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
36. Whorwell PJ, Altringer L, Morel J, et al,. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-90.
37. Engsbro AL, Simren M, Bytzer P,. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther 2012; 35: 350-9.
38. Guandalini S, Magazzu G, Chiaro A, et al,. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010; 51: 24-30.
39. Guyonnet D, Chassany O, Ducrotte P, et al,. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-86.
40. Kajander K, Hatakka K, Poussa T, et al,. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387-94.
41. Andriulli A, Neri M, Loguercio C, et al,. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol 2008; 42 (Suppl. 3): S218-23.
42. Niv E, Naftali T, Hallak R, Vaisman N,. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clinical Nutr 2005; 24: 925-31.
43. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D,. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253-8.
44. Hungin APS, Mulligan C, Pot B, et al,. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice-an evidence-based international guide. Aliment Pharmacol Ther 2013; 38: 864-86.